South Korea's Celltrion launched the domestic investor roadshow for a delayed W1 trillion ($881 million) initial public offering of its sales and distribution division on Monday, hoping to capitalise on robust investor sentiment towards biopharmaceutical IPOs.
¬ Haymarket Media Limited. All rights reserved.
